论文信息 - LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 - 字舞流文

LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

A. Carneiro | G. Long | L. Ny | C. Krepler | I. Márquez-Rodas | V. Atkinson | A. Spreafico | Scott J. Diede | Alan D. Smith | T. Petrella | A. Berrocal | A. Fernandez | R. Jamal | F. Svedman | L. Merino | S. O'Day | Kim Chen